Skip to main content

Advertisement

Figure 2 | Molecular Cancer

Figure 2

From: The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias

Figure 2

Characterisation of the RASSF10 gene. A, RT-PCR analysis showing expression of RASSF10 in normal human bone marrow. B, The 5' region of the RASSF10 transcript was amplified from normal human bone marrow using 5'RACE. Arrowed is the major product of 5'RACE which was cloned and sequenced to determine the transcription start point and open reading frame of the RASSF10 gene. C, Schematic summarising the structure of the RASSF10 gene and the open reading frame encoding a shortened protein of 507amino acids that does not contain the in silico predicted N-terminal 108 amino acids that are divergent from the RASSF7–9 proteins. D, ClustalW alignments of RASSF7–10 proteins including both the in silico predicted 615 amino acid RASSF10 [GenBank:NM_001080521] and the shorter 507 amino acid RASSF10 confirmed in this study suggesting the divergent N-terminal 108 amino acids is not likely to be part of the RASSF10 protein.

Back to article page